Therapeutic targeting of the pro-inflammatory cytokine TNFα was introduced as an efficient strategy to treat patients with autoimmune disorders such as rheumatoid arthritis and inflammatory bowel disease49. This evidence concerns the gene TNF and rheumatoid arthritis.